Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draft Biopharmaceutical Comparability Guideline Marks ICH Foray Into Manufacturing Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

Q5E will help industry design a comparability study and understand why the information is needed. FDA will publish a draft for comment by mid-February.

You may also be interested in...



FDA Creates CMC Pilots To Put Quality Assessment Principles Into Practice

NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.

GMP “Design Space” To Facilitate FDA Quality Initiative Implementation

“Design Space” is emerging as a pivotal concept in FDA’s effort to integrate its pharmaceutical application review and inspection operations into a new “quality assessment” system. With regulatory flexibility for manufacturing changes in the balance, the agency will be working with industry to refine the concept and its application in drug development and manufacturing.

FDA Estimates GSK Seizure Involves $4 Bil. Worth Of Product

FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet is the agency's largest in terms of monetary value, involving $4 bil. worth of product, the agency said

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel